Company Overview
Nuvectis Pharma, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the development of precision medicines designed to treat serious conditions characterized by unmet medical needs within the oncology sector. The company functions within the broader healthcare sector, specifically targeting the biotechnology industry, which implies a focus on high-risk, high-reward research and development cycles rather than immediate commercialization of established products. According to the available data, the company employs 13 individuals and maintains a total market capitalization of $210.87 million, while specific annual revenue figures are not disclosed in the provided financial records. The current market capitalization of $210.87 million indicates that the company holds a modest valuation relative to large-cap pharmaceutical peers, reflecting its status as a smaller entity with significant potential for expansion contingent upon successful clinical trial outcomes for its drug candidates.
Financial Health
The company reports a net income of $-28,871,000 over the trailing twelve months, while revenue and EBITDA figures are not disclosed in the current dataset. The substantial gap between the reported net income loss and the absence of positive revenue metrics suggests a cost structure dominated by research and development expenses typical of clinical-stage biotechnology firms. Free cash flow stands at $-6,832,750, indicating that the company is currently burning cash to fund its operations and clinical trials rather than generating surplus liquidity from daily business activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet achieved commercial profitability or that revenue recognition methods result in zero margin calculation at this stage of development. The company holds $31.63 million in cash reserves, whereas total debt and the debt-to-equity ratio are not applicable or disclosed, suggesting the balance sheet relies primarily on equity and cash rather than leveraged debt structures. With a current ratio of 2.38, the company demonstrates strong short-term liquidity, meaning it possesses more than twice the current assets necessary to cover its short-term liabilities. Return on Equity is -188.0% and Return on Assets is -68.5%, metrics that reveal management is currently utilizing shareholder capital and assets to generate significant losses rather than returns, a common characteristic of early-stage biotechnology companies prioritizing asset growth over immediate profit generation.
Valuation Assessment
The trailing twelve-month P/E ratio is not applicable, while the forward P/E ratio is listed as -8.29, implying that the market expects the company to remain in a loss position or that earnings are negative enough to invert the traditional valuation multiple. The price-to-book ratio is 11.10, indicating that the market is valuing the company at more than eleven times its book value, which often reflects the high intellectual property value and potential of clinical assets rather than current tangible assets. Since revenue is not available, the price-to-sales ratio is not applicable, and similarly, the EV/EBITDA multiple is not applicable, suggesting that traditional valuation multiples based on earnings or sales are not suitable for assessing this specific asset at this time. The stock has traded between a 52-week high of $11.52 and a 52-week low of $5.55, providing a historical range for investors to analyze price volatility without making future performance predictions. The beta value is -0.32, a negative coefficient that indicates the stock's price movements have historically moved inversely to the broader market, presenting a unique volatility profile distinct from standard equities.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not applicable, as the company has not generated sufficient revenue to calculate these growth rates in the current reporting period. Consequently, the company does not pay dividends, as evidenced by a dividend yield that is not applicable and a payout ratio of 0.0%. This lack of dividend distribution means the company retains all available earnings, however small or negative, to reinvest directly into research and development activities rather than returning capital to shareholders. The overall growth and income profile is defined by a complete reliance on external capital markets and internal cash reserves to fund future expansion, with no current contribution to shareholder income through dividends or earnings growth.